TY - JOUR
T1 - Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma
T2 - A Collaborative Effort on Behalf of the American Society for Transplantation and Cellular Therapy and the European Society for Blood and Marrow Transplantation
AU - Iqbal, Madiha
AU - Kumar, Ambuj
AU - Dreger, Peter
AU - Chavez, Julio
AU - Sauter, Craig S.
AU - Sureda, Anna M.
AU - Bachanova, Veronika
AU - Maziarz, Richard T.
AU - Dreyling, Martin
AU - Smith, Sonali M.
AU - Jacobson, Caron
AU - Glass, Bertram
AU - Casulo, Carla
AU - Oluwole, Olalekan O.
AU - Montoto, Silvia
AU - Advani, Ranjana
AU - Cohen, Jonathon
AU - Salles, Gilles
AU - Hamad, Nada
AU - Kuruvilla, John
AU - Kahl, Brad S.
AU - Shadman, Mazyar
AU - Kanate, Abraham S.
AU - Budde, Lihua Elizabeth
AU - Kamdar, Manali
AU - Flowers, Christopher
AU - Hamadani, Mehdi
AU - Kharfan-Dabaja, Mohamed A.
N1 - Publisher Copyright:
© 2024 The American Society for Transplantation and Cellular Therapy
PY - 2024/9
Y1 - 2024/9
N2 - Follicular lymphoma (FL) is the most common indolent B-cell non-Hodgkin lymphoma (NHL), accounting for nearly one-third of all NHL. The therapeutic landscape for patients with FL has significantly expanded over the past decade, but the disease continues to be considered incurable. Hematopoietic cell transplantation (HCT) is potentially curative in some cases. Recently, the emergence of chimeric antigen receptor T-cell therapy (CAR-T) for patients with relapsed/refractory (R/R) FL has yielded impressive response rates and long-term remissions, but definitive statement on the curative potential of CAR-T is currently not possible due to limited patient numbers and relatively short follow up. A consensus on the contemporary role, optimal timing, and sequencing of HCT (autologous or allogeneic) and cellular therapies in FL is needed. As a result, the American Society of Transplantation and Cellular Therapy (ASTCT) Committee on Practice Guidelines endorsed this effort to formulate consensus recommendations to address this unmet need. The RAND-modified Delphi method was used to generate 15 consensus statements/recommendations. These clinical practice recommendations will help guide clinicians managing patients with FL. Of note, the use of bispecific antibodies in R/R FL was not in the scope of this project.
AB - Follicular lymphoma (FL) is the most common indolent B-cell non-Hodgkin lymphoma (NHL), accounting for nearly one-third of all NHL. The therapeutic landscape for patients with FL has significantly expanded over the past decade, but the disease continues to be considered incurable. Hematopoietic cell transplantation (HCT) is potentially curative in some cases. Recently, the emergence of chimeric antigen receptor T-cell therapy (CAR-T) for patients with relapsed/refractory (R/R) FL has yielded impressive response rates and long-term remissions, but definitive statement on the curative potential of CAR-T is currently not possible due to limited patient numbers and relatively short follow up. A consensus on the contemporary role, optimal timing, and sequencing of HCT (autologous or allogeneic) and cellular therapies in FL is needed. As a result, the American Society of Transplantation and Cellular Therapy (ASTCT) Committee on Practice Guidelines endorsed this effort to formulate consensus recommendations to address this unmet need. The RAND-modified Delphi method was used to generate 15 consensus statements/recommendations. These clinical practice recommendations will help guide clinicians managing patients with FL. Of note, the use of bispecific antibodies in R/R FL was not in the scope of this project.
KW - allogeneic transplant
KW - autologous transplantation
KW - CAR T-cell therapy
KW - cellular therapy
KW - consensus
KW - Follicular lymphoma
UR - http://www.scopus.com/inward/record.url?scp=85199780052&partnerID=8YFLogxK
U2 - 10.1016/j.jtct.2024.06.025
DO - 10.1016/j.jtct.2024.06.025
M3 - Article
C2 - 38972511
AN - SCOPUS:85199780052
SN - 2666-6375
VL - 30
SP - 832
EP - 843
JO - Transplantation and Cellular Therapy
JF - Transplantation and Cellular Therapy
IS - 9
ER -